These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 29732991)
1. Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies. Patel P; Patel VK; Singh A; Jawaid T; Kamal M; Rajak H Curr Comput Aided Drug Des; 2019; 15(2):145-166. PubMed ID: 29732991 [TBL] [Abstract][Full Text] [Related]
2. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study. Choubey SK; Jeyaraman J J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885 [TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors. Abdizadeh T; Ghodsi R; Hadizadeh F Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):365-383. PubMed ID: 28482791 [TBL] [Abstract][Full Text] [Related]
4. Insights into structural features of HDAC1 and its selectivity inhibition elucidated by Molecular dynamic simulation and Molecular Docking. Sixto-López Y; Bello M; Correa-Basurto J J Biomol Struct Dyn; 2019 Feb; 37(3):584-610. PubMed ID: 29447615 [TBL] [Abstract][Full Text] [Related]
5. Fragment-Based Drug Design of Selective HDAC6 Inhibitors. Ruzic D; Djokovic N; Nikolic K Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126 [TBL] [Abstract][Full Text] [Related]
6. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities. Ortore G; Di Colo F; Martinelli A J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584 [TBL] [Abstract][Full Text] [Related]
7. Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations. Kollar J; Frecer V J Mol Graph Model; 2018 Oct; 85():97-110. PubMed ID: 30145395 [TBL] [Abstract][Full Text] [Related]
8. Common SAR Derived from Multiple QSAR Models on Vorinostat Derivatives Targeting HDACs in Tumor Treatment. Praseetha S; Bandaru S; Yadav M; Nayarisseri A; Sureshkumar S Curr Pharm Des; 2016; 22(33):5072-5078. PubMed ID: 27339433 [TBL] [Abstract][Full Text] [Related]
9. Fragment based G-QSAR and molecular dynamics based mechanistic simulations into hydroxamic-based HDAC inhibitors against spinocerebellar ataxia. Sinha S; Tyagi C; Goyal S; Jamal S; Somvanshi P; Grover A J Biomol Struct Dyn; 2016 Oct; 34(10):2281-95. PubMed ID: 26510381 [TBL] [Abstract][Full Text] [Related]
10. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors. Tripathy S; Azam MA; Jupudi S; Sahu SK J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860 [TBL] [Abstract][Full Text] [Related]
12. Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors. Sirous H; Campiani G; Brogi S; Calderone V; Chemi G Molecules; 2020 Apr; 25(8):. PubMed ID: 32331470 [TBL] [Abstract][Full Text] [Related]
13. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity. Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969 [TBL] [Abstract][Full Text] [Related]
14. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid. Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198 [TBL] [Abstract][Full Text] [Related]
15. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach. Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500 [TBL] [Abstract][Full Text] [Related]
16. Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening. Sirous H; Campiani G; Calderone V; Brogi S Comput Biol Med; 2021 Oct; 137():104808. PubMed ID: 34478925 [TBL] [Abstract][Full Text] [Related]
17. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses. Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726 [TBL] [Abstract][Full Text] [Related]
18. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction. Radhika V; Jaraf HA; Kanth SS; Vijjulatha M Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770 [TBL] [Abstract][Full Text] [Related]
19. Pharmacophore Based 3D-QSAR, Virtual Screening and Docking Studies on Novel Series of HDAC Inhibitors with Thiophen Linker as Anticancer Agents. Patel P; Singh A; Patel VK; Jain DK; Veerasamy R; Rajak H Comb Chem High Throughput Screen; 2016; 19(9):735-751. PubMed ID: 27487787 [TBL] [Abstract][Full Text] [Related]
20. Screening of Phytocompounds for Identification of Prospective Histone Deacetylase 1 (HDAC1) Inhibitor: An In Silico Molecular Docking, Molecular Dynamics Simulation, and MM-GBSA Approach. Bharadwaj KK; Ahmad I; Pati S; Ghosh A; Rabha B; Sarkar T; Bhattacharjya D; Patel H; Baishya D Appl Biochem Biotechnol; 2024 Jul; 196(7):3747-3764. PubMed ID: 37776441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]